Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7860013 | 1.00 | CA2 (0.48) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4902507 | 0.98 | CA2 (0.47) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6802942 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8186793 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28617729 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6802283 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6807996 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6797823 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL5206524 | 0.86 | — | — | |
| SCHEMBL288356 | 0.82 | S1PR2 (0.57) | CA2CA1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2289888-A2 | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them | SEIKAGAKU CORPORATION (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-2289887-A2 | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them | SEIKAGAKU CORPORATION (JP) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011014494-A1 | ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES | SCHERING CORPORATION (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ARRAY BIOPHARMA, INC. | 2009-08-13 | — | — | US | disclosed |
| US-7294616-B2 | Capreomycin derivatives and their use as antibacterials | ARRAY BIOPHARMA, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203585-A1 | CAPREOMYCIN DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | CAPRIN1, NISCH, RPIA | CA2 2562/4885CA1 4608/4885SLC1A3 4503/4885 |
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | CA2 450/4885CA1 2060/4885SLC1A3 3395/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | CA2 445/4885CA1 1635/4885SLC1A3 3095/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | CA2 395/4885CA1 1900/4885SLC1A3 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.